Welcome to our dedicated page for Coherus SEC filings (Ticker: CHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Coherus Oncology, Inc. (CHRS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, which Coherus uses to furnish quarterly financial results, report material events and disclose listing-related matters.
Recent Form 8-K filings show that Coherus Oncology reports quarterly earnings and business updates, including net revenue from continuing operations, research and development expenses associated with its immuno-oncology pipeline, and selling, general and administrative costs. These filings also describe trends in LOQTORZI net product revenue and provide context on how development of CHS-114 and casdozokitug contributes to overall spending.
Coherus’ SEC filings additionally document Nasdaq listing status. In a June 30, 2025 Form 8-K, the company reported receiving a deficiency notice related to the minimum bid price requirement. A subsequent Form 8-K dated September 5, 2025, reported that Coherus had regained compliance with Nasdaq Listing Rule 5550(a)(2) and was in full compliance with all continued listing standards of The Nasdaq Global Market.
Through Stock Titan, readers can follow these filings as they are made available on EDGAR, while AI-powered summaries help explain the key points in accessible language. This includes highlighting items such as results of operations, financing arrangements, divestitures, and other events that Coherus Oncology identifies as material to shareholders.
For investors analyzing CHRS, the filings page offers a structured view into the company’s financial condition, capital structure, and regulatory communications, complementing clinical and commercial news about LOQTORZI and the broader immuno-oncology pipeline.
Coherus Oncology, Inc. (CHRS) reported that it furnished, not filed, a press release announcing financial results for the fiscal quarter ended September 30, 2025. The company disclosed this under Item 2.02 and attached the full text as Exhibit 99.1.
The submission clarifies that the information provided under Item 2.02 and Exhibit 99.1 is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference unless specifically stated. The filing also includes the Cover Page Inline XBRL as Exhibit 104.
Coherus Oncology, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing. The company previously received a Nasdaq deficiency notice on June 30, 2025 after its common stock closed below $1.00 per share for 30 consecutive business days, giving it until December 29, 2025 to cure the issue.
On September 5, 2025, Nasdaq informed Coherus that the closing price of its common stock had been $1.00 or greater for the requisite period, restoring compliance with Listing Rule 5550(a)(2). Coherus is now in full compliance with all continued listing standards of the Nasdaq Global Market, removing the immediate risk associated with the prior deficiency notice.